<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05072704</url>
  </required_header>
  <id_info>
    <org_study_id>2021/04</org_study_id>
    <nct_id>NCT05072704</nct_id>
  </id_info>
  <brief_title>Opioid Free Anesthesia in Total Hip Arthroplasty</brief_title>
  <acronym>OFATHA</acronym>
  <official_title>Opioid Free Anesthesia in Total Hip Arthroplasty. A Randomized, Controlled and Triple-blind Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CMC Ambroise Paré</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CMC Ambroise Paré</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Total hip arthroplasty (THA) is one of the most common orthopedic surgical procedure and is&#xD;
      associated with severe pain in the immediate postoperative period, thus limiting early&#xD;
      recovery.&#xD;
&#xD;
      Postoperative pain management in THA requires multimodal analgesia, combining drugs and&#xD;
      injection of a local anesthetic (LA). But, the best anesthesia strategy to provide optimal&#xD;
      postoperative analgesia in THA remains controversial. Opioid free anesthesia could limit the&#xD;
      episodes of hyperalgesia as well as tolerance and addiction to opioids.&#xD;
&#xD;
      The hypothesis of this study is that an opioid free anesthesia using dexmedetomidine could&#xD;
      improve analgesia after THA.&#xD;
&#xD;
      The main objective of this monocenter, prospective, randomized, triple-blind, controlled&#xD;
      trial is to assess the interest of opioid free anesthesia using dexmedetomidine on morphine&#xD;
      consumption after THA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the pre-anaesthesia room, after the implementation of classical monitoring and a&#xD;
      peripheral venous catheter, all patients will receive an antibioprophylaxis according to SFAR&#xD;
      (French Society of Anesthesia &amp; Intensive Care Medecine) recommendations and injection of 10&#xD;
      mg of IV dexamethasone.&#xD;
&#xD;
      The patients will be then randomized in 2 groups:&#xD;
&#xD;
      Control group:&#xD;
&#xD;
        -  Pre-operative normal saline infusion 100 ml over 30 minutes&#xD;
&#xD;
        -  Injection of sufentanil 10 µg in normal saline 2 ml on induction of anesthesia&#xD;
&#xD;
      If needed after incision :&#xD;
&#xD;
        -  Per-operative normal saline infusion 100 ml&#xD;
&#xD;
        -  Per-operative injection of sufentanil 5 µg in normal saline 1 ml&#xD;
&#xD;
      OFA group (experimental group):&#xD;
&#xD;
        -  Pre-operative dexmedetomidine infusion 1 µg/kg in normal saline 100 ml over 30 minutes&#xD;
&#xD;
        -  Injection of normal saline 2 ml on induction of anesthesia&#xD;
&#xD;
      If needed after incision :&#xD;
&#xD;
        -  Per-operative dexmedetomidine infusion 0.4 µg/kg in normal saline 100 ml&#xD;
&#xD;
        -  Per-operative injection of normal saline 1 ml&#xD;
&#xD;
      In the operating room, general anesthesia will be induced by intravenous ketamine (0.4 mg/kg)&#xD;
      + propofol (3 mg/kg) +/- cisatracurium (0.1 mg/kg) for the introduction of laryngeal mask&#xD;
      airway. Anesthesia will be maintained with propofol.&#xD;
&#xD;
      Postoperative analgesia protocol :&#xD;
&#xD;
        -  Multimodal analgesia will be instituted during surgery by the administration of&#xD;
           paracetamol (1 g), nefopam (20 mg) and ketoprofen (100 mg) and the infiltration of the&#xD;
           surgical wound with 100 ml of ropivacaine 0.2%.&#xD;
&#xD;
        -  In post-anesthesia care unit (PACU): oxycodone titration if NRS (pain score) &gt;3&#xD;
           according to the centre's usual care.&#xD;
&#xD;
        -  In ward and at home: systematic per os analgesia with paracetamol (1 g, 4 times a day)&#xD;
           and ibuprofen (400 mg, 3 times a day); oxycodone (10 mg, lockout interval: 4 h) if NRS&#xD;
           (pain score) &gt;3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative analgesia, defined by the oxycodone consumption in the first 24 hours post-surgery</measure>
    <time_frame>24 hours</time_frame>
    <description>Postoperative cumulated dose of oxycodone in oral morphine equivalent (mg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analgesia in post-anesthesia care unit (PACU)</measure>
    <time_frame>6 hours</time_frame>
    <description>Total amount of oxycodone (mg) administered in PACU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain at rest</measure>
    <time_frame>24 hours</time_frame>
    <description>Postoperative pain at rest (numeric rating scale ranging from 0 to 10: 0= no pain; 10= worst imaginable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain at walk</measure>
    <time_frame>24 hours</time_frame>
    <description>Postoperative pain at mobilization (numeric rating scale ranging from 0 to 10: 0= no pain; 10= worst imaginable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects associated with opioids</measure>
    <time_frame>24 hours</time_frame>
    <description>Complications due to oxycodone (postoperative nausea and vomiting, drowsiness, acute urinary retention, pruritus, disorientation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects associated with dexmedetomidine</measure>
    <time_frame>24 hours</time_frame>
    <description>Complications due to dexmedetomidine (bradycardia defined by HR&lt;50 bpm or requiring the use of atropine; hypotension defined by SBP&lt;90 mmHg or requiring the use of vasoconstrictors; hypertension defined by SBP&gt;160 mmHg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outpatient care failure</measure>
    <time_frame>24 hours</time_frame>
    <description>Unplanned hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in post-anesthesia care unit (PACU)</measure>
    <time_frame>6 hours</time_frame>
    <description>Duration of PACU stay (min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recover the ability to walk</measure>
    <time_frame>12 hours</time_frame>
    <description>Duration for recovery the ability to walk (min)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Primary Total Hip Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sufentanil IV injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OFA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>Pre-operative injection of sufentanil 10µg in 2ml of normal saline on induction of anesthesia + per-operative injection of sufentanil 5µg in 1ml of normal saline during the surgery if needed.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Pre-operative infusion of dexmedetomidine 1µg/kg in 100ml of normal saline before surgery + per-operative infusion of dexmedetomidine 0.4 µg/kg in 100ml of normal saline during the surgery if needed.</description>
    <arm_group_label>OFA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years and older,&#xD;
&#xD;
          -  Undergoing outpatient primary total hip arthroplasty under general anesthesia with&#xD;
             laryngeal mask,&#xD;
&#xD;
          -  Consent for participation,&#xD;
&#xD;
          -  Affiliation to a social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Heart rate &lt; 60 bpm&#xD;
&#xD;
          -  Chronic pain syndrome requiring preoperative morphine use (class 3)&#xD;
&#xD;
          -  Contraindication for: paracetamol, ketoprofen, nefopam, oxycodone, propofol, ketamine,&#xD;
             cisatracurium, sufentanyl, ropivacaine.&#xD;
&#xD;
          -  Contraindication for dexmedetomidine: hypersensitivity to the active substance or to&#xD;
             any of the excipients, advanced cardiac block (grade 2 or 3) unless paced ;&#xD;
             uncontrolled hypotension ; acute cerebrovascular conditions&#xD;
&#xD;
          -  Contraindication to laryngeal mask : old insulin-dependent diabetes,&#xD;
             gastro-oesophageal reflux, morbid obesity (defined by BMI &gt; 35)&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Women of child bearing potential without contraception (any contraceptive method used&#xD;
             regularly and appropriately with a low failure rate: &lt;1% per year),&#xD;
&#xD;
          -  A mental or linguistic inability to understand the study,&#xD;
&#xD;
          -  Patient under protection of the adults (guardianship, curators or safeguard of&#xD;
             justice),&#xD;
&#xD;
          -  Patient included or planning to be included in another clinical trial relating to&#xD;
             medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alain Delbos, MD</last_name>
    <phone>05 62 13 29 97</phone>
    <phone_ext>+33</phone_ext>
    <email>alaindelbos@wanadoo.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Médipôle Garonne</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31036</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe Marty, MD</last_name>
      <phone>05 62 13 29 97</phone>
      <email>philippemarty@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 17, 2021</study_first_submitted>
  <study_first_submitted_qc>September 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hip arthroplasty</keyword>
  <keyword>Opioid free anesthesia</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Postoperative analgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

